ALEC (Alector) GF Score : 58/100 (As of Dec. 14, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alector GF Score?

Alector has the GF Score of 58, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 3/10
3. Growth Rank : 6/10
4. GF Value Rank : 4/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Alector might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Alector's GF Score

For the Biotechnology subindustry, Alector's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alector's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's GF Score distribution charts can be found below:

* The bar in red indicates where Alector's GF Score falls into.

Alector (NAS:ALEC) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Alector GF Score Related Terms

Thank you for viewing the detailed overview of Alector's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Alector Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

0Z2:Germany

Address

131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080

Website

https://www.alector.com

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Executives

Sara Kenkare-mitra	officer: President and Head of R&D	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano	officer: Chief Medical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal	director, officer: Chief Executive Officer	C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso	officer: Chief Financial Officer	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Polaris Venture Management Co. Vi, L.l.c.	10 percent owner	ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Terrance Mcguire	director, 10 percent owner	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner	director	C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Tillman U. Gerngross	director	C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr	director	C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Robert King	officer: Chief Development Officer	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman	officer: President and COO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080